Key terms
About KNSA
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KNSA news
Feb 28
12:00pm ET
Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)
Feb 28
7:32am ET
Kiniksa reports Q4 EPS 35c, consensus (14c)
Jan 05
4:32am ET
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA)
Jan 04
3:15pm ET
Strong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy Rating
Jan 04
7:42am ET
Kiniksa expects cash to fund operating plan into at least 2027
Jan 04
7:42am ET
Kiniksa says abiprubart Phase 2 trial meets primary efficacy endpoint
Jan 04
7:38am ET
Kiniksa sees 2024 ARCALYST net product revenue $360M-$380M
Jan 04
7:34am ET
Kiniksa reports Q4 ARCALYST net product revenue $71.2M
Jan 02
8:20am ET
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and UnitedHealth (UNH)
Jan 02
8:02am ET
Kiniksa price target raised to $25 from $23 at Wedbush
No recent news articles are available for KNSA
No recent press releases are available for KNSA
KNSA Financials
Key terms
Ad Feedback
KNSA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KNSA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range